Thomas Thomas T. - 14 Sep 2021 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Role: Director
Signature: /s/ Thomas T. Thomas
Issuer symbol: N/A
Transactions as of: 14 Sep 2021
Net transactions value: -$181
Form type: 4
Filing time: 16 Sep 2021, 16:14:53 UTC
Previous filing: 09 Sep 2021
Next filing: 23 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OPNT	Common Stock	Options Exercise	$250	+25	+0.38%	$10.00	6,678	14 Sep 2021	Direct
transaction	OPNT	Common Stock	Sale	$284	-15	-0.22%	$18.95	6,663	14 Sep 2021	Direct	F1, F2
transaction	OPNT	Common Stock	Options Exercise	$15,000	+1,500	+23%	$10.00	8,163	14 Sep 2021	Direct
transaction	OPNT	Common Stock	Sale	$15,096	-792	-9.7%	$19.06	7,371	14 Sep 2021	Direct	F1, F3
transaction	OPNT	Common Stock	Options Exercise	$15,000	+1,500	+20%	$10.00	8,871	14 Sep 2021	Direct
transaction	OPNT	Common Stock	Sale	$15,051	-764	-8.6%	$19.70	8,107	14 Sep 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OPNT	Stock Option (right to buy)	Options Exercise	$0	-25	-0.36%	$0.000000	6,834	14 Sep 2021	Common Stock	25	$10.00	Direct	F5, F6
transaction	OPNT	Stock Option (right to buy)	Options Exercise	$0	-1,500	-22%	$0.000000	5,334	14 Sep 2021	Common Stock	1,500	$10.00	Direct	F5, F6
transaction	OPNT	Stock Option (right to buy)	Options Exercise	$0	-1,500	-28%	$0.000000	3,834	14 Sep 2021	Common Stock	1,500	$10.00	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2	The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 10, after selling to cover the exercise price, will be held by the Reporting Person.
F3	The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 708, after selling to cover the exercise price, will be held by the Reporting Person.
F4	The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 736, after selling to cover the exercise price, will be held by the Reporting Person.
F5	The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F6	On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.